Revenue breakdown of the major CROs in China 2019, by segment
In 2019, pre-clinical contract research organizations (CROs) contributed the largest proportion of the total revenue of WuXi AppTec, amounting to around 6.47 billion yuan. Established in 2000 and went IPO in 2018, WuXi AppTech is one of the leading players in the Chinese pharmaceutical industry.